Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC527-X intraoperative imaging in prostate cancer (Phase II, single-center)
ChiCTR2500109000Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of NC527-X in prostate cancer (PCa) (4 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Missed Lesion Detection Rate (Patient-Level). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
NC527-X
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2500109000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109000.